학술논문
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
Document Type
Article
Author
Source
In: Nature Medicine . (Nature Medicine, March 2024, 30(3):896-904)
Subject
Language
English
ISSN
1546170X
10788956
10788956